MRK•benzinga•
Merck And Jiangsu Hengrui Pharmaceuticals Entered Into An Exclusive License Agreement For HRS-5346, An Investigational Oral Small Molecule Lipoprotein(a) Inhibitor Currently In A Phase 2 Trial In China, Hengrui Pharma Will Receive An Upfront Payment Of $2
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga